DECISION
www.epa.govt.nz
Date 20 June 2018
Application code APP203565
Application type
To develop in containment genetically modified organisms under
sections 40(1) and 42A of the Hazardous Substances and New
Organisms Act 1996
Applicants The New Zealand Institute for Plant & Food Research Limited
Date application received 12 June 2018
Consideration date 20 June 2018
Considered by The Acting General Manager Hazardous Substances and New
Organisms of the Environmental Protection Authority (EPA)1
Purpose of the application
To develop in containment, microorganisms and plant host
species to explore the function of plant genes which encode
proteins containing domains specifically rich in glutamine and
aspargine amino acids.
1. Summary of decision
1.1 Application APP203565 to develop, as a project, genetically modified organisms (as described in
Tables 1 and 2 of this decision) in containment is approved, with controls.
1.2 I had sufficient information to assess the application. The application was considered in accordance
with section 42A of the Hazardous Substances and New Organisms (HSNO) Act 1996 (‘the Act’), the
Hazardous Substances and New Organisms (Low-Risk Genetic Modification) Regulations 2003 (‘the
Regulations’), and the Hazardous Substances and New Organisms (Methodology) Order 1998 (‘the
Methodology’).
1.3 I note that in accordance with section 58(1)(c) of the HSNO Act, the Department of Conservation
(DOC) and the Ministry for Primary Industries (MPI) were given the opportunity to comment on this
1 The Acting General Manager Hazardous Substances and New Organisms of the EPA has made the decision on this application under delegated authority in accordance with section 19 of the Act.
2
Decision: APP203565
application. DOC indicated that this application did not appear to have any biodiversity implications,
and had no comments on it. MPI did not comment on the application.
2. The approved genetically modified organisms (GMOs) and the controls
imposed
Purpose of the project
2.1 The purpose of this application is to develop, by genetic modification, microorganisms and plant host
species to explore the function of plant genes which encode proteins containing domains specifically
rich in glutamine (Q) and asparagine (N) amino acids, also known as Q/N rich regions.
2.2 I determined that this application is for a valid purpose; the development of any new organism as
provided for in section 39(1)(a) of the Act.
Description of the organisms to be developed
2.3 Pursuant to section 42A(1), the application describes a project for the development of genetically
modified organisms, the identity of host organisms and the nature and range of the proposed genetic
modifications.
2.4 As per section 42A(2) of the Act, I was satisfied that the host organisms and the proposed genetic
modifications conform to the requirements of:
Category 1/2 host organisms (as per clause 7(1) of the Regulations), and
Category A/B genetic modifications (as per clause 5(1) of the Regulations) (as described in Tables
1 and 2).
Table 1: Approved organism description
Host
organisms
Microorganisms
Escherichia coli (Migula, 1895) Castellani and Chalmers 1919, non-pathogenic laboratory adapted strains
Agrobacterium tumefaciens (Smith and Townsend, 1907) Conn 1942, disarmed
strains
Saccharomyces cerevisiae Meyen ex EC Hansen (1883), non-pathogenic laboratory adapted strains
Pichia pastoris Guillerm Phaff (1956), non-pathogenic laboratory adapted strains
Ogataea angusta (Teun., H.H. Hall & Wick) Suh & Zhou 2010 (synonym Pichia angusta), non-pathogenic laboratory adapted strains
Schizosaccharomyces pombe Lindner 1893, non-pathogenic laboratory adapted
strains non-sporulating strains
3
Decision: APP203565
Tissue culture plants, protoplasts and plant cell cultures (without reproductive structures and kept in closed containers)
Nicotiana spp. L. and Graham
Arabidopsis thaliana Heynh.
Petunia spp. Juss.
Marchantia polymorpha (marchantia) L.
Category of
host organism
Host microorganisms are Category 1 host organisms because they:
are clearly identifiable and classifiable
are characterised to the extent that their main biological characteristics are
known
are not normally able to (or contain infectious agents normally able to) cause
disease in humans, animals, plants or fungi
do not normally infect, colonise or establish in humans, and
do not produce desiccation-resistant structures such as spores or cysts that can
be normally disseminated in the air.
Tissue culture plants, protoplasts and plant cell cultures (without reproductiove structures
and kept in closed containers) are Category 1 host organisms because they:
are clearly identifiable and classifiable
They are characterised to the extent that their main biological characteristics are
known
are not normally able to (or contain infectious agents normally able to) cause
disease in humans, animals, plants or fungi
do not normally infect, colonise or establish in humans, and
do not produce desiccation-resistant structures such as spores or cysts that can
be normally disseminated in the air
will not have reproductive structures and will be kept in closed containers.
Modifications Standard non-conjugative cloning, binary or expression plasmid vectors may be used to
integrate DNA sequences into the plant, bacterial or yeast strains for protein expression,
gene functions studies, and/or transformation of plants (either transient or stable
transformation). Vectors such as pBin, pCambia, pArt, pMon, and oNov may be used for
expression studies; pHANNIBAL, pKANNIBAL, pHELLSGATE GatewayTM may be used
for RNAi research, and pPopoff series may be used for inducible expression.
Transformation might be effected by, but is not limited to, Agrobacterium transformation
and biolistics.
Vectors may consist of regulatory elements including promoters, multiple cloning sites,
origins of replication, operators, binding sequences, inducible promoter elements, flanking
sequences, recombination sites, sequences that facilitate recombination, protein
purification tags, enhancer and silencer sequences, recombination sequences and
recombinases, origin of conjugative transfer, suppressing sequences, polyadenylation
signals, intron/exon slice sites, secretory and targeting signals, reporter and selectable
marker genes, antibiotic resistance genes, ribosomal binding sites, transcriptional
activators, transcriptional response elements,enhancers and transcriptional terminators
and Agrobacterium, T-DNA and P-DNA border elements, T-DNA/P-DNA processing and
transfer sequences, and other elements outside the T-DNA or P-DNA regions. These
regulatory elements may be sourced from plant, bacterial, fungal (including yeast), viral or
bacteriophage origin.
4
Decision: APP203565
Donor genetic material may be sourced from the genomic DNA or complementary DNA
of bacteria, fungi (including yeast), plant, viral and synthetic sources. The gene contents
specifically sourced from plant species might contain genes with a high Q/N rich region.
Target genes/cDNA sequences may be incorporated in sense or antisense orientations.
RNAi technology (excluding viral induced gene silencing) may also be used to limit the
production of target proteins.
Modifications may include heterologous gene expression and precision genome editing,
involving the use of vectors carrying engineered DNA binding proteins, to facilitate gene
knockout (mutation and deletion), transcriptional activation or repression, nucleic acid
insertion (both sense and anti-sense and including nucleotide substitutions). Engineered
DNA binding proteins include, but are not limited to Zinc Fingers (ZFs), Transcriptional
activator like effectors (TALEs), and clustered regularly interspaced short palindromic
repeat-CRISPR associated protein 9 nucleases (CRISPR-Cas9). Gene sequences
involved in pigment binding of host organisms might be also studied.
Molecular tools may contain human derived DNA sequences. Such standard molecular
tools will be sourced from overseas and will not contain DNA of Māori origin.
Some viral DNA from viruses that infect plants will be used, however, only defined
segments of the viral genome that regulates transcription (eg. The 35S promoter) and
transcriptional terminator sequences of the viral genome will be used.
The modifications will exclude:
Genetic material that is derived from CITES-listed species
DNA that is directly derived from humans
The production of infectious particles normally able to cause disease in humans,
animals, plants, or fungi
Genetic material that intentionally increases the pathogenicity, virulence, or
infectivity of the host organism
Genes that encode for vertebrate toxins with an LD50 < 100 µg/kg
Modifications that result in the GMO having a greater ability to escape from
containment than the unmodified host organism
Genetic material derived from New Zealand native or taonga flora and fauna,
unless consultation has been conducted with representatives of appropriate iwi
Uncharacterised sequences from pathogenic microorganisms
RNAi technology that includes viral induced gene silencing
Category of
modifications
The modifications are Category A because they:
involve category 1 host organisms, as defined in the Regulations
are carried out under a minimum of PC1 containment as defined in the
Regulations
do not increase the pathogenicity, virulence or infectivity of the host organism to
laboratory personnel, the community or the environment
do not result in the GMO having a greater ability to escape from containment
than the unmodified host organism.
Minimum
containment
level required
PC1
5
Decision: APP203565
Table 2: Approved organism description
Host
organisms
Microorganisms
Agrobacterium tumefaciens (Smith and Townsend, 1907) Conn 1942, armed
strains
Whole plants or tissue cultures (either with or without reproductive structres and kept or not kept in closed containers)
Nicotiana spp. L. and Graham
Arabidopsis thaliana Heynh.
Petunia spp. Juss.
Marchantia polymorpha (marchantia) L.
Category of
host organism
Armed strains of Agrobacterium tumefaciens are Category 2 host organisms because
they are:
clearly identifiable and classifiable
characterised to the extent that their main biological characteristics are
known
micro-organisms of risk group 2 that are or contain an infectious agent
pathogenic to humans, animals, plants, or fungi
Whole plants or tissue cultures of Nicotiana spp. , Petunia spp. , and Arabidopsis
thaliana (either with or without reproductive structures and kept or not kept in closed
containers) are Category 2 host organisms because they are:
clearly identifiable and classifiable
with or without reproductive structures and will not be kept in closed
containers
Whole plants or tissue cultures of Marchantia polymorpha (either with or without
reproductive structures and kept or not kept in closed containers) are Category 2 host
organism because they are:
clearly identifiable and classifiable
Risk Group 2 organisms as defined in the Regulations that produce
desiccation-reistant structures such as spores or cysts that can be normally
disseminated in the air,
with or without reproductive structures and will not be kept in closed
containers
Modifications Standard non-conjugative cloning, binary or expression plasmid vectors may be used to
integrate DNA sequences into the plant, bacterial or yeast strains for protein expression,
gene functions studies, and/or transformation of plants (either transient or stable
transformation). Vectors such as pBin, pCambia, pArt, pMon, and oNov may be used for
expression studies; pHANNIBAL, pKANNIBAL, pHELLSGATE GatewayTM may be used
for RNAi research, and pPopoff series may be used for inducible expression.
Transformation might be effected by, but is not limited to, Agrobacterium transformation
and biolistics.
6
Decision: APP203565
Vectors may consist of regulatory elements including promoters, multiple cloning sites,
origins of replication, operators, binding sequences, inducible promoter elements, flanking
sequences, recombination sites, sequences that facilitate recombination, protein
purification tags, enhancer and silencer sequences, recombination sequences and
recombinases, origin of conjugative transfer, suppressing sequences, polyadenylation
signals, intron/exon slice sites, secretory and targeting signals, reporter and selectable
marker genes, antibiotic resistance genes, ribosomal binding sites, transcriptional
activators, transcriptional response elements,enhancers and transcriptional terminators
and Agrobacterium, T-DNA and P-DNA border elements, T-DNA/P-DNA processing and
transfer sequences, and other elements outside the T-DNA or P-DNA regions. These
regulatory elements may be sourced from plant, bacterial, fungal (including yeast), viral or
bacteriophage origin.
Donor genetic material may be sourced from the genomic DNA or complementary DNA
of bacteria, fungi (including yeast), plant, viral and synthetic sources. The gene contents
specifically sourcing from plant species might be containing genes with high Q/N rich
region. Target genes/cDNA sequences may be incorporated in sense or antisense
orientations. RNAi technology (excluding viral induced gene silencing) may also be used
to limit the production of target proteins.
Modifications may include heterologous expression and precision genome editing,
involving the use of vectors carrying engineered DNA binding proteins, to facilitate gene
knockout (mutation and deletion), gene transcriptional activation or repression, gene or
nucleic acid insertion (both sense and anti-sense and including nucleotide substitutions).
Engineered DNA binding proteins include, but are not limited to Zinc Fingers (ZFs),
Transcriptional activator like effectors (TALEs), and clustered regularly interspaced short
palindromic repeat-CRISPR associated protein 9 nucleases (CRISPR-Cas9). Gene
sequences involved in pigment binding of host organisms might be also studied.
Molecular tools may contain human derived DNA sequences. Such molecular tools will be
sourced from oversease and will not contain DNA of Māori origin.
Some viral DNA from viruses that infect plants will be used, however, only defined
segments of the viral genome that regulates transcription (eg. The 35S promoter) and
transcriptional terminator sequences of the viral genome will be used.
The modifications will exclude:
Genetic material that is derived from CITES-listed species
DNA that is directly derived from humans
The production of infectious particles normally able to cause disease in humans,
animals, plants, or fungi
Genetic material that intentionally increases the pathogenicity, virulence, or
infectivity of the host organism
Genes that encode for vertebrate toxins with an LD50 < 100 µg/kg
Modifications that result in the GMO having a greater ability to escape from
containment than the unmodified host organism
Genetic material derived from New Zealand native or taonga flora and fauna,
unless consultation has been conducted with representatives of appropriate iwi
Uncharacterised sequences from pathogenic microorganisms
RNAi technology that includes viral induced gene silencing
7
Decision: APP203565
Category of
modifications
The modifications to whole plants or tissue cultures are Category B because they:
involve category 2 host organisms, as defined in the Regulations
are carried out under a minimum of PC2 containment as defined in the
Regulations
involves a host organism that is not normally able to cause disease in humans,
animals, plants, or fungi
do not increase the pathogenicity, virulence or infectivity of the host organism to
laboratory personnel, the community or the environment
do not result in the GMO having a greater ability to escape from containment
than the unmodified host organism.
The modifications to armed strains of Agrobacterium tumefaciens are Category B
because they:
involve category 2 host organisms, as defined in the Regulations
are carried out under a minimum of PC2 containment as defined in the
Regulations
involves a host organism that is normally able to cause disease in humans,
animals, plants, or fungi provided that the nucleic acid that is introduced is
characterised to the extent that
o Its sequence is known, and
o Its gene function is understood; and
o Its potential gene products are understood
do not increase the pathogenicity, virulence or infectivity of the host organism to
laboratory personnel, the community or the environment
do not result in the GMO having a greater ability to escape from containment
than the unmodified host organism.
Minimum
containment
level required
PC2
2.5 I considered that this project represents a particular line of scientific inquiry and has clearly defined
objectives to develop the organisms specified in Tables 1 and 2, to develop in containment,
microorganisms and plant host species to explore the function of plant genes which encode proteins
containing domains specifically rich in glutamine and aspargine amino acids. This will allow the work
described above.
3. Rapid assessment of adverse effects of the project
3.1 As the host organisms and genetic modifications meet the criteria of low-risk genetic modification (as
described in the Regulations), I have made a rapid assessment of the adverse effects of carrying out
the project (as per section 42A(2) of the Act).
3.2 I note that the GMOs would first need to escape from the containment facility into the environment to
cause non-negligible adverse effects. However, as the GMOs will be developed within approved
8
Decision: APP203565
containment facilities which have structural requirements and operational procedures to prevent the
escape of the GMOs, I consider that it would be highly improbable that the GMOs will escape from
containment.
3.3 I did not identify any non-negligible adverse effects on the environment, public health, market
economy or New Zealand’s international obligations.
3.4 I did not identify any non-negligible adverse effects on personnel handling the GMOs as exposure to
the GMOs is voluntary and those personnel are trained to safely handle the GMOs.
3.5 I did not identify any non-negligible adverse effects on society and community as:
The GMOs will be developed within approved containment facilities which have structural
requirements and operational procedures to prevent the escape of the GMOs
The GMOs do not involve host organisms or genetic modifications that I consider will adversely
affect society and community.
3.6 I did not identify non-negligible adverse effects on Māori and their culture and traditions with their
ancestral lands, water, sites, waahi tapu, valued flora and fauna, and other taonga as:
The GMOs will be developed within approved containment facilities which have structural
requirements and operational procedures to prevent their escape
The host organisms do not include native or valued flora and fauna
Genetic material will not be derived from Māori.
4. The decision-making
4.1 I had sufficient information to assess the application as submitted by the applicant.
4.2 As per section 42A(3) of the Act, after completing a rapid assessment of adverse effects, I have
decided to approve the application and impose controls providing for each of the matters specified in
Schedule 3 as I think fit.
4.3 The matters to be addressed by containment controls for developing GMOs are listed in Part 1 of
Schedule 3 of the Act. To address these, controls must be imposed to:
limit the likelihood of any accidental release of any organism or any viable material
exclude unauthorised people from the facility
exclude other organisms from the facility and control undesirable and unwanted organisms within
the facility
prevent the unintended release of the organisms by experimenters working with the organisms
control the effects of any accidental release or escape of the organisms, and
specify inspection and monitoring requirements for the containment facilities.
9
Decision: APP203565
4.4 I imposed the controls detailed in Table 3 to provide for the matters above and any other matters I
considered necessary to give effect to the purpose of the Act.
4.5 I note that the applicant has detailed their containment regime in section 4.2 of the application. I
consider that this containment regime is adequate, since the genetic modifications will be carried out
in MPI-approved facilities at a minimum of a PC1 standard for category A genentic modifications, and
at a minimum of PC2 for category B genetic modifications.
10
Decision: APP203565
Table 3: Controls
The approval holder must ensure compliance with the following controls
1) This approval is limited to develop in containment, microorganisms and plant host species described in
tables 1 and 2, to explore the function of plant genes which encode proteins containing domains rich in
glutamine and aspargine.
2) The approved organism must not escape containment.
3) The approved organisms must be developed within a containment facility that complies with:
The MAF/ERMA New Zealand Standard: Facilities for Microorganisms and Cell Cultures2: 2007a;
The Australian/New Zealand Standard AS/NZS 2243.3:2002 Safety in laboratories: Part 3:
Microbiological aspects and containment facilities3; and
Physical Containment level 1 (PC1) requirements of the above Standards (at minimum) for
category A genetic modifications of microorganisms
Physical Containment level 2 (PC2) requirements of the above Standards (at minimum) for
category B genetic modifications of microorganisms
4) The approved organisms must be developed within a containment facility that complies with:
The MAF/ERMA New Zealand Standard: Facilities for Plants 20074
The Australian/New Zealand Standard AS/NZS 2243.3:2002 Safety in laboratories: Part 3:
Microbiological aspects and containment facilities5; and
Physical Containment level 1 (PC1) requirements of the above Standards (at minimum) for
category A genetic modifications involving tissue culture plants, protoplasts or plant cell cultures
kept in closed containers and without reproductive structures
Physical Containment level 2 (PC2) requirements of the above Standards (at minimum) for
category B genetic modifications involving whole plants and tissue cultures kept or not kept in a
closed container and with or without reproductive structures
5) Given asexual reproduction of Merchantia polymorpha liverworts is via gemma that form in splash cups
on the thallus surface, water must not be directly applied to Merchantia polymorpha thalli.
6) Male and female Merchantia polymorpha thalli must be kept separated
7) The approval holder must ensure that within 24 hours of the discovery of any breach of containment
(includes the escape of an organism(s) or a failure in the structural integrity of physical containment),
2 Any reference to MAF/ERMA New Zealand or AS/NZS Standards in these controls also refers to any subsequent
version approved or endorsed by the EPA. 3 Any reference to MAF/ERMA New Zealand or AS/NZS Standards in these controls also refers to any subsequent version approved or endorsed by the EPA. 4 Any reference to MAF/ERMA New Zealand or AS/NZS Standards in these controls also refers to any subsequent
version approved or endorsed by the EPA. 5 Any reference to MAF/ERMA New Zealand or AS/NZS Standards in these controls also refers to any subsequent version approved or endorsed by the EPA.
11
Decision: APP203565
the Ministry for Primary Industries biosecurity inspector responsible for supervision of the facility, has
received notification (written or verbal)6 of the breach and the details of any remedial action taken.
4.6 The applicant is not, in this instance, required to provide progress reports as this application does not
raise any novel issues.
4.7 I have not imposed an expiry date on this approval.
5. Summary of the decision
5.1 Application APP203565, to develop in containment GMOs (as described in Tables 1 and 2 of this
decision), is approved, with controls under section 42A(3) (as described in Table 3 of this decision).
This decision was based on the information supplied by the applicant and was considered in
accordance with section 42A of the Act, the Regulations, and the Methodology.
20 June 2018
Gayle Holmes
Acting General Manager, Hazardous
Substances and New Organisms
Environmental Protection Authority
Date
6 The biosecurity inspector’s contact details can be found in the facility containment manual.
12
Decision: APP203565
Approval codes for organisms on application APP203565
Host organisms
Approval number Organism
GMD102339 Escherichia coli (Migula 1895), Castellani and Chalmers 1919 non-
pathogenic laboratory adapted strains
GMD102340 Agrobacterium tumefaciens (Smith and Townsend, 1907) Conn 1942, armed and disarmed strains
GMD102341 Saccharomyces cerevisiae Meyen ex EC Hansen (1883), non-
pathogenic laboratory adapted strains
GMD102342 Pichia pastoris Guillerm Phaff (1956), non-pathogenic laboratory adapted strains
GMD102343 Ogataea angusta (Teun., H.H. Hall & Wick) Suh & Zhou 2010 (synonym Pichia angusta), non-pathogenic laboratory adapted strains
GMD102344 Schizosaccharomyces pombe Lindner 1893, non-pathogenic laboratory
adapted strains non-sporulating strains
GMD102345 Marchantia polymorpha (marchantia) L., tissue culture plants, protoplast and plant cell cultures, whole plants or tissue cultures
GMD102346 Nicotiana spp. L. and Graham, tissue culture plants, protoplast and plant cell cultures, whole plants or tissue cultures
GMD102347 Arabidopsis thaliana Heynh., tissue culture plants, protoplast and plant
cell cultures, whole plants or tissue cultures
GMD102348 Petunia spp. Juss., tissue culture plants, protoplast and plant cell cultures, whole plants or tissue cultures